WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Canaccord Genuity 35th Annual Growth Conference. ImmunoGen President and CEO Daniel Junius will discuss the Company in a “fireside chat” moderated question and answer session that will be webcast beginning at 1 pm ET on August 12, 2015.
Help employers find you! Check out all the jobs and post your resume.
